Mobile

A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients w...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000286-19

A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• Investigate the antiproteinuric effect of increasing dose administration of Aliskiren versus Aliskiren matching placebo

Critère d'inclusion

  • Hypertension

Liens